MBCI.US MabCure Inc
- Market cap
- USD 78.00
- P/E
- -
- P/B
- 0.06x
- ROE
- -321.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2011.
Is MBCI.US undervalued?
Graham numberThe Graham number of MabCure Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MabCure Inc fundamental analysis
No fundamental analysis for MabCure Inc yet.
MabCure Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MabCure Inc
MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new bus…
Full company profileMabCure Inc financial statements
MabCure Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 500K |
| Gross Profit | - | - | 0.00 | 0.00 | 0.00 | 500K |
| Operating Income | -4.00K | -106K | -536K | -1.36M | -1.02M | -710K |
| EBITDA | -4.00K | -106K | -525K | -1.32M | -976K | -12.0M |
| Net Income | -4.00K | -106K | -531K | -1.39M | -1.43M | -12.5M |
| EPS | 0.00 | 0.00 | -0.01 | -0.02 | -0.02 | -0.20 |
| Balance Sheet | ||||||
| Total Assets | 51.0K | - | 19.5M | 18.9M | 16.2M | 4.81M |
| Total Liabilities | - | 49.3K | 286K | 833K | 483K | 935K |
| Shareholders' Equity | 51.0K | -49.3K | 19.2M | 18.1M | 15.7M | 3.88M |
| Cash & Short-term Investments | 45.0K | - | 811K | 214K | 3.42K | 146K |
| Total Debt | - | - | 181K | 651K | 186K | 261K |
| Cash Flow | ||||||
| Operating Cash Flow | -6.00K | -90.3K | -455K | -1.03M | -692K | -61.4K |
| Capital Expenditure | 0.00 | 0.00 | 170K | 44.4K | 14.0K | 1.27K |
| Free Cash Flow | -6.00K | -90.3K | -625K | -1.08M | -706K | -62.7K |
| Ratios | ||||||
| ROE | -7.8% | - | -2.8% | -7.7% | -9.1% | -321.2% |
| ROA | -7.8% | - | -2.7% | -7.3% | -8.8% | -258.8% |
| Net Profit Margin | - | - | - | - | - | -2,490.3% |
| Debt to Equity | - | - | 0.01x | 0.04x | 0.01x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MabCure Inc dividends
MabCure Inc has not paid dividends in the last 6 fiscal years.
Last stock split: 20:1 on Nov 26, 2007.
Who owns MabCure Inc
Ownership data of MabCure Inc is not available yet.
MabCure Inc company profile
- Company name
- MabCure Inc
- Ticker
- MBCI.US
- Exchange
- USA Stocks
- Sector
- Technology
- Industry
- Semiconductors & Semiconductor Equipment
- Employees
- 3
- Fiscal year end
- December
- Address
- 21 Sparrow Circle, White Plains, NY, United States, 10605
- Phone
- 845 591 3144
- Website
- -
About MabCure Inc
MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new business plan. MabCure, Inc. was founded in 2006 and is based in White Plains, New York.
MabCure Inc management
1- Mr. Jehu Thomas Degerold Hand Esq.Chief Executive & Financial Officer and Director · born 1957